[(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: A sample of the complexed mometasone furoate monohydrate stock suspension (4 g) was mixed with an appropriate diluent (27.2 g) (deionized water or saline (0.9% NaCl/deionized water (w/w)) and mixed thoroughly to obtain the 0.05% w/w mometasone formulations containing 0.097% HPMC, 0.002% sodium lauryl sulfate, 0.014% methylparaben sodium, 0.016% citric acid anhydrous, 0.009% potassium sorbate and approximately 0.5 ppm of 30% simethicone emulsion. mixed thoroughly

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: A sample of the complexed mometasone furoate monohydrate stock suspension (4 g) was mixed with an appropriate diluent (27.2 g) (deionized water or saline (0.9% NaCl/deionized water (w/w)) and mixed thoroughly to obtain the 0.05% w/w mometasone formulations containing 0.097% HPMC, 0.002% sodium lauryl sulfate, 0.014% methylparaben sodium, 0.016% citric acid anhydrous, 0.009% potassium sorbate and approximately 0.5 ppm of 30% simethicone emulsion. mixed thoroughly